Atorvastatin Exerts Antileukemia Activity via Inhibiting Mevalonate-YAP Axis in K562 and HL60 Cells

Atorvastatin Exerts Antileukemia Activity via Inhibiting Mevalonate-YAP Axis in K562 and HL60 Cells

Novel therapeutic strategies are still urgently expected for leukemia despite undisputed success of various targeted therapeutics. The antileukemia activity of Atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on human leukemia cells was investigated. Atorvastatin...

Full description

Bibliographic Details
Main Authors: Lei Zhang, Ting Chen, Yonghai Dou, Shaolu Zhang, Hongyan Liu, Tungalagtamir Khishignyam, Xiaofei Li, Duo Zuo, Zhe Zhang, Meihua Jin, Ran Wang, Yuling Qiu, YuXu Zhong, Dexin Kong
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-10-01
Series:Frontiers in Oncology
Subjects:
Atorvastatin
anti-leukemia
mevalonate-YAP axis
cell cycle
apoptosis
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.01032/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.01032/full

Similar Items